P58.4 Neonatal jaundice due to drugs or toxins transmitted from mother or given to newborn

Name of the Condition

• Neonatal jaundice due to drugs or toxins transmitted from mother or given to newborn
• ICD-10-CM Code: P58.4

Summary

This condition describes jaundice in a newborn resulting from elevated bilirubin levels caused by exposure to drugs or toxins. The exposure may occur via maternal transmission during pregnancy or direct administration to the newborn. It is characterized by yellowing of the skin and eyes due to bilirubin accumulation, which can arise when substances interfere with bilirubin metabolism or increase red blood cell breakdown.

Causes

Neonatal jaundice in this context is caused by drugs or toxins that affect bilirubin processing or red blood cell stability. Maternal use of certain medications (e.g., sulfonamides, vitamin K antagonists) or toxins during pregnancy can cross the placenta and impact the newborn. Direct administration of substances to the newborn, such as certain antibiotics or herbal remedies, may also disrupt bilirubin clearance or increase hemolysis, leading to jaundice.

Risk Factors

• Maternal use of medications or toxins during pregnancy that cross the placenta
• Direct administration of drugs or substances to the newborn
• Prematurity (reduced liver maturity and bilirubin clearance capacity)
• Underlying metabolic or hepatic immaturity in the newborn
• Exposure to environmental toxins or contaminated substances

Symptoms

• Yellowing of the skin and eyes (jaundice)
• Dark urine or pale stools
• Lethargy or poor feeding
• Irritability or high-pitched crying
• In severe cases, signs of bilirubin encephalopathy (e.g., arching, seizures)

Diagnosis

Diagnosis involves assessing bilirubin levels (total and direct) and evaluating for hemolysis. A detailed maternal and newborn medication history is critical to identify potential drug or toxin exposure. Laboratory tests may include blood counts, liver function tests, and toxicology screening if exposure is suspected. Imaging or additional tests may be used to rule out other causes of jaundice.

Treatment Options

Treatment focuses on managing bilirubin levels and addressing the underlying exposure. Phototherapy is commonly used to reduce bilirubin. If a specific drug or toxin is identified, discontinuation or avoidance is key. In severe cases, exchange transfusion may be necessary. Supportive care, such as hydration and feeding support, is also provided.

Prognosis and Follow-Up

Prognosis depends on the severity of bilirubin elevation and timely intervention. Most cases resolve with appropriate treatment, but delayed care can lead to complications. Follow-up includes monitoring bilirubin levels and assessing for long-term effects, especially if bilirubin encephalopathy occurred. Regular check-ups are recommended to ensure normal development.

Complications

• Bilirubin encephalopathy (kernicterus) with potential neurological damage
• Hearing loss or developmental delays from severe jaundice
• Liver dysfunction if the underlying cause is hepatotoxic
• Prolonged jaundice requiring extended treatment

Lifestyle & Prevention

Prevention involves careful medication management during pregnancy and newborn care. Healthcare providers should review maternal drug use and avoid unnecessary substances. Newborns should not receive unapproved medications or toxins. Educating caregivers about safe practices and consulting providers before using any substances is important.

When to Seek Professional Help

Seek immediate medical attention if the newborn shows signs of jaundice (yellowing of skin/eyes), lethargy, poor feeding, or irritability. Prompt evaluation is crucial to prevent severe bilirubin elevation. Contact a healthcare provider if jaundice worsens or if there is a known or suspected drug/toxin exposure.

Tips for Medical Coders

Document the specific drug or toxin involved, including maternal use or direct newborn administration, to support code assignment. Note the timing of exposure relative to birth and any associated lab results (e.g., bilirubin levels). Ensure the record clarifies whether the cause is maternal transmission or direct newborn exposure, as this impacts coding accuracy.